Literature DB >> 2004319

Extracolonic malignancies in inflammatory bowel disease.

A Ekbom1, C Helmick, M Zack, H O Adami.   

Abstract

A population-based cohort with inflammatory bowel disease consisting of 4776 patients (3121 with ulcerative colitis and 1655 with Crohn's disease) was followed for 1 to 50 years for the occurrence of malignant neoplasms. Two hundred eighty-three cancers were observed versus 189.1 expected (standardized incidence ratio [SIR] = 1.5, 95% confidence limits [CL] 1.3 to 1.7). One hundred seventy-eight extracolonic cancers were observed versus 168.8 expected (SIR = 1.1, 95% CL 0.9 to 1.2). In Crohn's disease and extensive ulcerative colitis, observed cases were close to those expected but in ulcerative proctitis, the relative risk of extracolonic cancers was close to significantly increased (SIR = 1.3, 95% CL 1.0 to 1.7). Squamous skin cancers after Crohn's disease (SIR = 5.5, 95% CL 2.0 to 11.9) and connective tissue cancers after ulcerative colitis (SIR = 4.0, 95% CL 1.0 to 10.2) were significantly increased. Those having extensive ulcerative colitis at diagnosis had an increased risk of brain cancers (SIR = 2.4, 95% CL 1.0 to 4.6). Patients with extensive ulcerative colitis had lower than expected risk of breast cancer (SIR = 0.4, 95% CL 0.1 to 1.0).

Entities:  

Mesh:

Year:  1991        PMID: 2004319     DOI: 10.1002/1097-0142(19910401)67:7<2015::aid-cncr2820670731>3.0.co;2-r

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  35 in total

Review 1.  Infliximab treatment for Crohn's disease.

Authors:  C A Conroy; R Cattell
Journal:  Postgrad Med J       Date:  2001-07       Impact factor: 2.401

2.  Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low.

Authors:  R J Farrell; Y Ang; P Kileen; D S O'Briain; D Kelleher; P W Keeling; D G Weir
Journal:  Gut       Date:  2000-10       Impact factor: 23.059

3.  Balancing the risks and benefits of infliximab in the treatment of inflammatory bowel disease.

Authors:  W J Sandborn; E V Loftus
Journal:  Gut       Date:  2004-06       Impact factor: 23.059

4.  p53 mutations are associated with dysplasia and progression of dysplasia in patients with Crohn's disease.

Authors:  Jeffrey W Nathanson; Nicole E Yadron; Jeanne Farnan; Sydney Kinnear; John Hart; David T Rubin
Journal:  Dig Dis Sci       Date:  2007-08-04       Impact factor: 3.199

Review 5.  Risk of cancer in ulcerative colitis.

Authors:  A Ekbom
Journal:  J Gastrointest Surg       Date:  1998 Jul-Aug       Impact factor: 3.452

Review 6.  ACG Clinical Guideline: Preventive Care in Inflammatory Bowel Disease.

Authors:  Francis A Farraye; Gil Y Melmed; Gary R Lichtenstein; Sunanda V Kane
Journal:  Am J Gastroenterol       Date:  2017-01-10       Impact factor: 10.864

7.  Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease.

Authors:  Millie D Long; Hans H Herfarth; Clare A Pipkin; Carol Q Porter; Robert S Sandler; Michael D Kappelman
Journal:  Clin Gastroenterol Hepatol       Date:  2010-01-16       Impact factor: 11.382

Review 8.  Cancer in inflammatory bowel disease.

Authors:  Jianlin Xie; Steven H Itzkowitz
Journal:  World J Gastroenterol       Date:  2008-01-21       Impact factor: 5.742

Review 9.  Treatment of inflammatory bowel disease: a review of medical therapy.

Authors:  Patricia L Kozuch; Stephen B Hanauer
Journal:  World J Gastroenterol       Date:  2008-01-21       Impact factor: 5.742

10.  Prevalence of gastrointestinal diseases in two British national birth cohorts.

Authors:  A G C Ehlin; S M Montgomery; A Ekbom; R E Pounder; A J Wakefield
Journal:  Gut       Date:  2003-08       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.